The Menopause Misconception: A Business of Omissions and Inaction

The healthcare industry’s handling of menopause is a case study in missed opportunities and unfulfilled promises. Conversations between Norah O’Donnell and her doctor, Rachel Rubin, have shed light on the often-overlooked condition, with implications extending far beyond individual lives to the broader economy.

Menopause can be described as a “castration event,” a blunt phrase that accurately conveys the sudden loss of hormone production affecting millions worldwide. The consequences are multifaceted: hot flashes, sleep disturbances, mood swings, and weight gain become common complaints. Unlike men, who experience a natural decline in testosterone levels with age, women essentially run on fumes.

Symptoms vary from woman to woman, but one aspect stands out: urinary tract infections (UTIs) are alarmingly common during and after menopause. Untreated UTIs can lead to severe health complications, including sepsis, hospitalization, and death. Dr. Rubin advocates for offering vaginal hormones to all menopausal women, which can prevent UTIs by restoring the urinary tract’s microbiome.

The economic benefits of addressing menopause more comprehensively are substantial. According to Dr. Rubin, widespread use of vaginal estrogen could save Medicare between $6 billion and $22 billion annually – a staggering figure highlighting the business case for better health.

Progress is lacking in one area: testosterone replacement therapy (TRT) for women. Despite global consensus on its benefits for low libido in menopausal and perimenopausal women, there remains no FDA-approved TRT product specifically designed for women. This omission leaves patients with limited options – a situation that Dr. Rubin’s patient base is trying to change through off-label prescriptions.

O’Donnell’s personal experience using testosterone prescribed by Rubin raises questions about the medical establishment’s priorities. If even high-profile individuals like O’Donnell are navigating uncharted territory, what does this say about the broader lack of support for women’s health?

The healthcare industry often touts innovative treatments and breakthroughs, but when it comes to menopause, the response is notably inconsistent. This inconsistency creates a market where patients must navigate complex systems, seek out specialized care, or – in some cases – turn to off-label prescriptions as a last resort.

As we reflect on the business of menopause, it’s clear that this condition has become a symbol of broader healthcare inequities. By ignoring or downplaying the needs of postmenopausal women, policymakers and medical professionals are leaving billions of dollars on the table – not to mention countless lives forever changed by inadequate care.

A comprehensive reassessment of how healthcare providers address menopause is long overdue. We need to prioritize prevention, treatment options, and patient-centered care. Only then can we hope to unlock improved health outcomes and substantial economic savings – both of which are within our grasp, but remain elusive due to our collective failure to act.